Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Executive Summary
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.
You may also be interested in...
New Translational Science Team Created In US FDA’s CDER To Aid Rare Disease Drug Development
The group is intended to help rare disease drug developers answer all the necessary questions about surrogate endpoints and markers before the application review cycle.
GOP Accelerated Approval Proposal Could Expand Eligibility For US FDA Pathway
The rival to House Energy and Commerce Committee Chair Frank Pallone’s bill would not set expiration dates for accelerated approvals.
PDUFA VII: US FDA Will Offer Additional Meetings To Boost Rare Disease Endpoint Development
If they reach a public disclosure agreement, a handful of sponsors will be admitted to a new pilot program that allows four meetings with the FDA on rare disease endpoint issues.